A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
The purpose of this study is to assess the safety and efficacy of parsaclisib in subjects with relapsed or refractory diffuse large B-cell lymphoma.
Lymphoma
DRUG: Parsaclisib
Objective Response Rate Based on Lugano Classification Criteria in Group A, Defined as the percentage of subjects with a complete or partial response as defined by Lugano Classification criteria for lymphomas (Cheson et al 2014) as determined by IRC., Every 9 weeks through Week 27, then every 18 weeks thereafter until disease progression, up to 26 months
Duration of Response in Group A, Defined as the time from first documented evidence of complete or partial response until disease progression or death from any cause among subjects who achieve an objective response as determined by IRC., Every 9 weeks through Week 27, then every 18 weeks thereafter until disease progression, up to 26 months|Progression-free Survival in Group A, Defined as the time from the date of the first dose of study drug until the earliest date of disease progression, as determined by radiographic disease assessment as provided by an IRC., Every 9 weeks through Week 27, then every 18 weeks thereafter until disease progression, up to 26 months|Overall Survival (OS) in Group A, Defined as the time from the date of the first dose of study drug until death by any cause., From first dose of study drug until death by any cause; up to 26 months|Safety as Assessed by Percentage of Subjects With Adverse Events in Group A and Group B, A TEAE is any AE either reported for the first time or worsening of a pre-existing event after the first dose of parsaclisib until 30 days after the last dose administration., Screening through 35 days after end of treatment, up to 42 months
The purpose of this study is to assess the safety and efficacy of parsaclisib in subjects with relapsed or refractory diffuse large B-cell lymphoma.